BGB-3245+Panitumumab in Advanced/Metastatic RAS mutant CRC & Pancreatic Ductal Cancers (MapKure)

Purpose of this Study

We are doing this study to see if the combination of an experimental drug called BGB-3245 (the study drug) and panitumumab is a safe and effective option for patients who have colorectal or pancreatic cancer with an RAS mutation.

Who Can Participate?

Eligibility

Adults ages 18+ who:
- Are diagnosed with advanced or metastatic RAS mutant colorectal cancer; OR
- Are diagnosed with RAS mutant pancreatic ductal cancer

For more information about who can join this study, please contact the study team at gi-oncology-cru@dm.duke.edu or 919-668-1861.

What is Involved?

If you choose to join this study, you will:
- Take the study drug in combination with panitumumab
- Have a tumor biopsy done, if necessary
- Have blood draws
- Have imaging scans (CT or MRI)

Study Details

Full Title

A Phase 1b, Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 with Panitumumab in
Patients with Advanced or Metastatic RAS mutant Colorectal and Pancreatic Ductal Cancers

Principal Investigator

John
Strickler

Protocol Number

PRO00114943

NCT ID

NCT06194877

Phase

I

Enrollment Status

Open to Enrollment